Form 8-K bluebird bio, Inc. For: Nov 05
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- S&P 500, Nasdaq close lower, dragged by Alphabet and megacap tech; focus on Iran
- Oil settles down more 3% after US-Iran talks signal easing supply risks
- Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
- Alan Greenspan, influential former Federal Reserve chair, dies at 100
- Buy gold stocks as valuations are cheap amid macro tension: BofA
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
- Qtrex Quantum executives plan to buy up to 2M shares over 12 months
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
Goldman Sachs Downgrades bluebird bio (BLUE) to Sell
November 8, 2021 7:38 AM ESTGoldman Sachs analyst Salveen Richter downgraded bluebird bio (NASDAQ: BLUE) from Neutral to Sell with a price target of $10.00 (from $23.00).
The analyst comments "We downgrade BLUE to Sell from Neutral and lower our 12-month PT to $10 from $23. Post the separation of the severe genetic disease (SGD; BLUE) and oncology businesses (2seventy bio; TSVT), BLUE is focused on developing and... More
Morgan Stanley Downgrades bluebird bio (BLUE) to Underweight, 'commercialization will remain challenging'
November 8, 2021 5:11 AM ESTMorgan Stanley analyst Matthew Harrison downgraded bluebird bio (NASDAQ: BLUE) from Equalweight to Underweight with a price target of $11.00 (from $19.00).
The analyst comments "Bluebird has developed a robust portfolio of genetherapies where we expect approval in 2022/2023. However, we believe the ultimate market for... More
